Furthermore, the limited benefit of Eve, particularly in hormone receptor-negative BC, is counterbalanced by a high toxicity due to off-target actions of the drug, particularly grade 3–4 neutropenia and stomatitis [1,2]. This evidence concerns the gene NR4A1 and neutropenia.